Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension

Journal of Cardiology

Volumn 39, Issue 4, 2002, Pages 195-204

  Hirono, Osamu ^a   Fatema, Kaniz ^a   Nitobe, Joji ^a   Takeishi, Yasuchika ^a   Kaneko, Kazuyoshi ^a   Shiga, Ryoko ^b   Kubota, Isao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b Department of Internal Medicine   (Japan)

Author keywords

Calcium channel blocking drugs; Collagen; Echocardiography, transthoracic; Hypertension; Hypertrophy

Indexed keywords

BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN TYPE 1; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; COLLAGEN; DIHYDROPYRIDINE DERIVATIVE;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DRUG EFFECT; ENZYME BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; FIBROSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPOTENSION; LONG TERM CARE; MALE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; AGED; BLOOD; HYPERTENSION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; CALCIUM CHANNEL BLOCKERS; COLLAGEN; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0036549159     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Krumholz HM, Larson M, Levy D: Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879-884
2. Diez J, Laviades C, Mayor G, Gil MJ, Monreal I: Increased serum concentrations of procollagen peptides in essential hypertension: Relation to cardiac alterations. Circulation 1995; 91: 1450-1456
3. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI: Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988; 62: 757-765
4. Diez J, Laviades C, Varo N, Querejeta R, Lopez B: Biochemical diagnosis of hypertensive myocardial fibrosis. Rev Esp Cardiol 2000; 53(Suppl 1): 8-13 (in Spanish with Eng abstr)
5. Mukherjee D, Sen S: Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: Role of blood pressure. J Mol Cell Cardiol 1993; 25: 185-196
6. Funck RC, Wilke A, Rupp H, Brilla CG: Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997; 432: 35-44
7. Seccia TM, Bettini E, Vulpis V, Quartaroli M, Trist DG, Gaviraghi G, Pirrelli A: Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats. Blood Press 1999; 8: 57-64
8. Rossi MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16: 1031-1041
9. Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994; 23: 869-877
10. Eleftheriades EG, Durand JB, Ferguson AG, Engelmann GL, Jones SB, Samarel AM: Regulation of procollagen metabolism in the pressure-overloaded rat heart. J Clin Invest 1993; 91: 1113-1122
11. Caulfield JB, Janucki JS: Structure and function of myocardial fibrillar collagen. Technol Health Care 1997; 5: 95-113
12. Brilla CG, Reams GP, Maisch B, Weber KT: Renin-angiotensin system and myocardial fibrosis in hypertension: Regulation of the myocardial collagen matrix. Eur Heart J 1993; 14(Suppl): 57-61
13. Brilla CG, Maisch B, Weber KT: Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: In vivo and in vitro studies on collagen matrix regulation. Clin Investig 1993; 71 (Suppl): S35-S41
14. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J: Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-540
15. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, Defreyte G, Soloway PJ, ZiIe MR, Spinale FG: Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 2000; 32: 109-120
16. Varo N, Iraburu MJ, Varela M, Lopez B, Etayo JC, Diez J: Chronic AT (1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35: 1197-1202
17. Kobayashi N, Nakano S, Mori Y, Kobayashi T, Tsubokou Y, Matsuoka H: Benidipine inhibits expression of ET-1 and TGF-β 1 in Dahl salt-sensitive hypertensive rats. Hypertens Res 2001; 24: 241-250
18. Fuji Y, Suzuki H, Katsumata H, Nakajima S, Saruta T: Hormonal and renal responses to oral once-daily calcium entry blocker in normotensive and hypertensive persons. J Cardiovasc Pharmacol 1988; 11: 438-443
19. Izawa H, Yokota M, Sobue T, Inagaki H, Koide M, Maeda M, Saito F, Miyahara T: long-term effects of benidipine on the regression of left ventricular hypertrophy in essential hypertension. Jpn J Clin Pharmacol Ther 1996; 27: 583-588
20. The sixth report of the joint national committee on the prevention, detection, evaluation, and treatment of high blood pressure. NIH publication 1997; 98: 4080
21. World Health Organization: Hypertension control. in Report of a WHO Expert Committee. World Health Organization, Geneva, 1996
22. Fujimoto N, Iwata K: Enzyme immunoassays for matrix metalloproteinases and their inhibitors. Connect Tissue Res 1994; 26: 237-244
23. Zhang J, Fujimoto N, Iwata K, Sakai T, Okada Y, Hayakawa T: A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 1 (interstitial collagenase) using monoclonal antibodies. Clin Chim Acta 1993; 219: 1-14
24. Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T: Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases: An application for rheumatoid arthritis serum and plasma. J Immunol Methods 1990; 127: 103-108
25. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 1977; 55: 613-618
26. Geiser EA, Bove KE: Calculation of left ventricular mass and relative wall thickness. Arch Pathol 1974; 97: 13-21
27. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH: Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-1558
28. Tsotetsi OJ, Woodiwiss AJ, Netjhardt M, Qubu D, Brooksbank R, Norton GR: Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats. Hypertension 2001; 38: 846-851
29. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C: Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55: 575-581
30. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Martinez Ubago JL, Diez J: Usefulness of serum carboxyterminar propeptide of procollagen type I is assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-291
31. Sugihara N, Genda A, Shimizu M, Suematu T, kita Y, Horita Y, Takeda R: Quantitation of myocardial fibrosis and its relation to function in essential hypertension and hypertrophic cardiomyopathy. Clin Cardiol 1988; 11: 771-778
32. Sugihara N, Genda A, Shimizu M, Suematsu T, Kita Y, Minamoto M, Kawagoshi H, Umeda K, Chin S, Takeda R: Diastolic dysfunction and its relation to myocardial fibrosis in essential hypertension. J Cardiol 1988; 18: 353- 361 (in Jpn with Eng abstr)
33. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Diez J: Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729-1735
34. Lip GY: Regression of left ventricular hypertrophy and improved prognosis: Some hope now...or hype? Circulation 2001; 104: 1582-1584
35. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study: Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32: 989-997
36. Devereux RB, Dahlof B: Criteria for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens 1994; 8: 735-739
37. Sagastagoitia JD, Morillas M, Martinez A, Lage E, Pallares C, Ugartemendia C, Asin E, Barrios V, Julia J, Sanchez P, Calvo C, Gonzalez J, Pina C, Garcia-Barbal J, Arnau C: Improvement in diastolic function in hypertensive patients with left ventricular hypertrophy with inhibitors of the angiotensin converting enzyme. Rev Clin Esp 1998; 198: 15-22 (in Spanish with Eng abstr)
38. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT, Dahlof B: Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: The prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001; 104: 1248-1254
39. Dollery CM, McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-868
40. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292
41. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, Heath JK: Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6: 1899-1904
42. Porreca E, Di Febbo C, Mincione G, Reale M, Baccante G, Guglielmi MD, Cuccurullo F, Colletta G: Increased transforming growth factor-beta production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997; 30: 134-139
43. Robert V, Besse S, Sabri A, Silvestre JS, Assayag P, Nguyen VT, Swynghedauw B, Delcayre C: Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest 1997; 76: 729-738
44. Manicourt DH, Fujimoto N, Obata K, Thonar EJ: Serum levels of collagenase, stromelysin-1, and TIMP-1: Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratin sulfate in patients with osteoarthritis. Arthritis Rheum 1994; 37: 1774-1783
45. Akiyama K, Shikata K, Sugimoto H, Matsuda M, Shikata Y, Fujimoto N, Obata K, Matsui H, Makino H: Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol 1997; 95: 115-128
46. Marti HP: Role of matrix metalloproteinases in the progression of renal lesions. Presse Med 2000; 29: 811-817 (in French with Eng abstr)
47. Ebihara I, Nakamura T, Tomino Y, Shimada N, Koide H: Metalloproteinase-9 mRNA expression in monocytes from patients with chronic renal failure. Am J Nephrol 1998; 18: 305-310
48. Campbell SE, Katwa LC: Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 1997; 29: 1947-1958
49. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993; 92: 1366-1372
50. Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994; 23: 869-877
51. Cruickshank JM, Lewis J, Moore V, Dodd C: Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992; 6: 85-90
52. Yamazaki T, Komuro I, Zou Y, Kudoh S, Shiojima I, Mizuno T, Hiroi Y, Nagai R, Yazaki Y: Efficient inhibition of the development of cardiac remodeling by a long-acting calcium antagonist amlodipine. Hypertension 1998; 31: 32-38
53. Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E, Schuurman FH, Meyboom-de Jong B, Crijns HJ: Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: The ELVERA trial. J Hypertens 2001; 19: 303-309